RBC puts NeuroMetrix at outperform

RBC Capital Markets analyst William R. Quirk rated NeuroMetrix Inc. at outperform, speculative risk, after the company's strong quarter, with revenue increasing 73.1% to $14.0 million and adjusted earnings per share of $0.16, above RBC's street high projection of $13.1 million and $0.06 adjusted earnings per share estimate. Biosensor revenue also beat expectations at $12.0 million. The company's shares are a favorite long-term micro-cap idea, according to the analyst.. Shares of the Waltham, Mass.-based medical device company were up $3.94, or 13.99%, at $32.11 on volume of 774,515 shares versus the three-month running average of 226,261 shares. (Nasdaq: NURO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.